Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease

Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 after previous approval in Europe and other countr...

Descripción completa

Detalles Bibliográficos
Autores principales: Weimbs, Thomas, Shillingford, Jonathan M, Torres, Jacob, Kruger, Samantha L, Bourgeois, Bryan C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295603/
https://www.ncbi.nlm.nih.gov/pubmed/30581563
http://dx.doi.org/10.1093/ckj/sfy089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295603/
https://www.ncbi.nlm.nih.gov/pubmed/30581563
http://dx.doi.org/10.1093/ckj/sfy089

Ejemplares similares